Pharma: Page 20
-
Getty Images
Is anyone taking the world’s priciest drugs?
A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.
By Meagan Parrish • Aug. 30, 2024 -
Getty Images
As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.
By Michael Gibney • Aug. 27, 2024 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Takeda Pharmaceuticals
Q&A // First 90 DaysWith a new oncology R&D head, Takeda revamps its strategy
The company is using a “three-by-four” approach to sharpen its cancer R&D aims.
By Alexandra Pecci • Aug. 27, 2024 -
Getty Images
Pharmas’ IRA court losses mount. They keep pursuing them.
The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.
By Amy Baxter • Aug. 26, 2024 -
Mario Tama/ via Getty Images
As a new mpox strain gains ground, a key drug stumbles in the clinic
Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.
By Kelly Bilodeau • Aug. 26, 2024 -
Getty Images
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.
By Alexandra Pecci • Aug. 22, 2024 -
Drew Angerer via Getty Images
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
The Supreme Court case added another layer of uncertainty on the regulatory front and opened up the Inflation Reduction Act to more legal attacks.
By Amy Baxter • Aug. 21, 2024 -
Courtesy of 23andMe
Q&A23andMe inches closer to cancer immunotherapy, guided by its genetic database
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
By Michael Gibney • Aug. 20, 2024 -
Getty Images
Novo plans new plant as it races to meet drug demand
The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.
By Ned Pagliarulo • Aug. 19, 2024 -
Getty Images
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.
By Kelly Bilodeau • Aug. 19, 2024 -
Kena Betancur via Getty Images
The drugs hit hardest by Medicare price negotiations
The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.
By Amy Baxter • Aug. 16, 2024 -
Scott Olson via Getty Images
Medicare reveals results of drug price negotiations
The agency said the first round of pricing talks, which involved drugs like the blood thinners Eliquis and Xarelto, will result in $6 billion in savings for taxpayers.
By Ned Pagliarulo • Aug. 15, 2024 -
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
By Michael Gibney • Aug. 15, 2024 -
Andreas Rentz via Getty Images
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
The German biotech is leveraging its mRNA platforms to develop a new class of cancer treatments that are necessary to lift the company’s flagging sales.
By Amy Baxter • Aug. 14, 2024 -
Permission granted by Immunic Therapeutics
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.
By Alexandra Pecci • Aug. 13, 2024 -
Getty Images
M&A is ready to explode, and that’s good news for pharma layoffs
Deals driven by obesity meds are fueling an M&A comeback, driving the industry to take fewer cost-cutting measures.
By Kelly Bilodeau • Aug. 12, 2024 -
Spencer Platt via Getty Images
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
By Amy Baxter • Aug. 9, 2024 -
Courtesy of Roche
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
By Jacob Bell • Aug. 8, 2024 -
Mario Tama / Getty via Getty Images
Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half
The top drugs at each of the world’s most valuable pharma companies tell the story of just how much the industry has changed over the course of a few years.
By Michael Gibney • Aug. 8, 2024 -
Permission granted by Moderna
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.
By Michael Gibney • Aug. 6, 2024 -
Getty Images
In a Duchenne market beset by problems, Capricor data marks a bright spot
The company’s cell therapy recently showed positive results from a mid-stage trial.
By Kelly Bilodeau • Aug. 5, 2024 -
Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024 -
Drew Angerer via Getty Images
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
The CEO noted how Pfizer's danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly's orforglipron.
By Jonathan Gardner • Aug. 1, 2024 -
Getty Images
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
By Alexandra Pecci • Aug. 1, 2024 -
Spencer Platt / Staff via Getty Images
3 Big Pharma cancer drugs facing inflation penalties
The U.S. government will demand payment from Big Pharma to make up for dozens of drugs with prices that rose faster than the rate of inflation.
By Amy Baxter • July 31, 2024
Previous
